Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

HISUN PHARM (600267.SS)

Compare
8.80
-0.20
(-2.22%)
At close: 3:00:04 PM GMT+8
Loading Chart for 600267.SS
  • Previous Close 9.00
  • Open 8.97
  • Bid 8.80 x --
  • Ask 8.81 x --
  • Day's Range 8.79 - 9.05
  • 52 Week Range 6.76 - 9.72
  • Volume 15,650,962
  • Avg. Volume 16,839,997
  • Market Cap (intraday) 10.79B
  • Beta (5Y Monthly) 0.59
  • PE Ratio (TTM) 18.72
  • EPS (TTM) 0.47
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date May 19, 2023
  • 1y Target Est --

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients and finished dosage form products. It offers products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, liver care, and orthopaedics treatment; and weight loss, anti-viral, anti-TB, animal healthcare, and others. The company also exports its products to approximately 70 countries worldwide. The company was founded in 1956 and is headquartered in Taizhou, China.

www.hisunpharm.com

8,062

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600267.SS

View More

Performance Overview: 600267.SS

Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600267.SS
6.02%
SSE Composite Index (000001.SS)
2.24%

1-Year Return

600267.SS
18.44%
SSE Composite Index (000001.SS)
6.59%

3-Year Return

600267.SS
25.77%
SSE Composite Index (000001.SS)
2.54%

5-Year Return

600267.SS
45.45%
SSE Composite Index (000001.SS)
15.44%

Compare To: 600267.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600267.SS

View More

Valuation Measures

Annual
As of 4/17/2025
  • Market Cap

    10.79B

  • Enterprise Value

    13.40B

  • Trailing P/E

    18.75

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.06

  • Price/Book (mrq)

    1.26

  • Enterprise Value/Revenue

    1.38

  • Enterprise Value/EBITDA

    16.05

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.21%

  • Return on Assets (ttm)

    0.99%

  • Return on Equity (ttm)

    -0.52%

  • Revenue (ttm)

    9.55B

  • Net Income Avi to Common (ttm)

    -20.24M

  • Diluted EPS (ttm)

    0.47

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.48B

  • Total Debt/Equity (mrq)

    55.23%

  • Levered Free Cash Flow (ttm)

    1.47B

Research Analysis: 600267.SS

View More

Company Insights: 600267.SS

Research Reports: 600267.SS

View More

People Also Watch